{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:30:20Z","timestamp":1781109020693,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hepatic steatosis is recognized as a major risk factor for liver disease progression and impaired response to interferon based therapy in chronic hepatitis C (CHC) patients. The mechanism of response to interferon-alpha (IFN-\u03b1) therapy under the condition of hepatic steatosis is unexplored. We investigated the effect of hepatocellular steatosis on hepatitis C virus (HCV) replication and IFN-\u03b1 antiviral response in a cell culture model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sub-genomic replicon (S3-GFP) and HCV infected Huh-7.5 cells were cultured with a mixture of saturated (palmitate) and unsaturated (oleate) long-chain free fatty acids (FFA). Intracytoplasmic fat accumulation in these cells was visualized by Nile red staining and electron microscopy then quantified by microfluorometry. The effect of FFA treatment on HCV replication and IFN-\u03b1 antiviral response was measured by flow cytometric analysis, Renilla luciferase activity, and real-time RT-PCR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>FFA treatment induced dose dependent hepatocellular steatosis and lipid droplet accumulation in the HCV replicon cells was confirmed by Nile red staining, microfluorometry, and by electron microscopy. Intracellular fat accumulation supports replication more in the persistently HCV infected culture than in the sub-genomic replicon (S3-GFP) cell line. FFA treatment also partially blocked IFN-\u03b1 response and viral clearance by reducing the phosphorylation of Stat1 and Stat2 dependent IFN-\u03b2 promoter activation. We show that FFA treatment induces endoplasmic reticulum (ER) stress response and down regulates the IFNAR1 chain of the type I IFN receptor leading to defective Jak-Stat signaling and impaired antiviral response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These results suggest that intracellular fat accumulation in HCV cell culture induces ER stress, defective Jak-Stat signaling, and attenuates the antiviral response, thus providing an explanation to the clinical observation regarding how hepatocellular steatosis influences IFN-\u03b1 response in CHC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-9-143","type":"journal-article","created":{"date-parts":[[2012,8,3]],"date-time":"2012-08-03T14:14:13Z","timestamp":1344003253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture"],"prefix":"10.1186","volume":"9","author":[{"given":"Feyza","family":"Gunduz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma M","family":"Aboulnasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha K","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidhartha","family":"Hazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret","family":"Poat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren P","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A","family":"Balart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanta","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,3]]},"reference":[{"key":"1850_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1053\/j.gastro.2004.09.013","volume":"127","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004, 127: 27-34. 10.1053\/j.gastro.2004.09.013.","journal-title":"Gastroenterology"},{"key":"1850_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2006","unstructured":"Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2006, 5: 558-567.","journal-title":"Lancet Infect Dis"},{"key":"1850_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-2893.1999.00178.x","volume":"6","author":"S Deuffic","year":"1999","unstructured":"Deuffic S, Poynard T, Valleron AJ: Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat. 1999, 6: 411-413. 10.1046\/j.1365-2893.1999.00178.x.","journal-title":"J Viral Hepat"},{"key":"1850_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009, 49: 1335-1374. 10.1002\/hep.22759.","journal-title":"Hepatology"},{"key":"1850_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/hep.20139","volume":"39","author":"B Gao","year":"2004","unstructured":"Gao B, Hong F, Radaeva S: Host factors and failure of interferon alpha treatment in hepatitis C virus. Hepatology. 2004, 39: 880-890. 10.1002\/hep.20139.","journal-title":"Hepatology"},{"key":"1850_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cld.2006.08.002","volume":"10","author":"P Puri","year":"2006","unstructured":"Puri P, Sanyal AJ: Role of obesity, insulin resistance and steatosis in hepatitis C virus infection. Clin Liver Dis. 2006, 10: 703-819.","journal-title":"Clin Liver Dis"},{"key":"1850_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1478-3231.2010.02397.x","volume":"31","author":"A Sanyal","year":"2011","unstructured":"Sanyal A: Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int. 2011, 31: 23-28.","journal-title":"Liver Int"},{"key":"1850_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2893.2009.01186.x","volume":"16","author":"F Negro","year":"2009","unstructured":"Negro F, Clement S: Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat. 2009, 16: 681-688. 10.1111\/j.1365-2893.2009.01186.x.","journal-title":"J Viral Hepat"},{"key":"1850_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1478-3231.2008.01945.x","volume":"29","author":"A Alberti","year":"2009","unstructured":"Alberti A: What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?. Liver Int. 2009, 29: 15-18.","journal-title":"Liver Int"},{"key":"1850_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1478-3231.2005.01082.x","volume":"25","author":"S Dash","year":"2005","unstructured":"Dash S, Prabhu R, Hazari S, Luo G, Bastian F, Garry RF, Zou W, Haque S, Joshi B, Regenstein FG, Thung SN: Interferon alpha, beta, gamma each inhibits hepatitis C virus replication at the levels of internal ribosome entry site mediated translation. Liver Int. 2005, 25: 1-15. 10.1111\/j.1478-3231.2005.01012.x.","journal-title":"Liver Int"},{"key":"1850_CR11","doi-asserted-by":"publisher","first-page":"10769","DOI":"10.1128\/JVI.77.20.10769-10779.2003","volume":"77","author":"J Guo","year":"2003","unstructured":"Guo J, Zhu Q, Seeger C: Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus sub genomic replicons. J Virol. 2003, 77: 10769-10779. 10.1128\/JVI.77.20.10769-10779.2003.","journal-title":"J Virol"},{"key":"1850_CR12","doi-asserted-by":"publisher","first-page":"11148","DOI":"10.1128\/JVI.76.21.11148-11154.2002","volume":"76","author":"IW Cheney","year":"2002","unstructured":"Cheney IW, Lai VCH, Zhong W, Brodhag T, Dempsey S, Lim C, Hong Z, Lau JYN, Tam RC: Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol. 2002, 76: 11148-11154. 10.1128\/JVI.76.21.11148-11154.2002.","journal-title":"J Virol"},{"key":"1850_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0166-0934(03)00134-4","volume":"110","author":"JM Vrolijk","year":"2003","unstructured":"Vrolijk JM, Kaul A, Hanson BE, Lohmann V, Haagmans BL, Schalm SW, Bartenschalager R: A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods. 2003, 110: 201-209. 10.1016\/S0166-0934(03)00134-4.","journal-title":"J Virol Methods"},{"key":"1850_CR14","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1128\/JVI.77.7.3898-3912.2003","volume":"77","author":"C Wang","year":"2003","unstructured":"Wang C, Pflugheber J, Sumpter R, Sodora DL, Hui D, Sen G, Gale M: Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol. 2003, 77: 3898-3912. 10.1128\/JVI.77.7.3898-3912.2003.","journal-title":"J Virol"},{"key":"1850_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/gut.2009.192732","volume":"59","author":"F Negro","year":"2010","unstructured":"Negro F: Abnormalities of lipid metabolisms in hepatitis C virus infection. Gut. 2010, 59: 1279-1287. 10.1136\/gut.2009.192732.","journal-title":"Gut"},{"key":"1850_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.clinre.2011.01.011","volume":"35","author":"F Negro","year":"2011","unstructured":"Negro F: Mechanisms of hepatitis C virus-related insulin resistance. Clin Res Hepatol Gastroenterol. 2011, 35: 358-363. 10.1016\/j.clinre.2011.01.011.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1850_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/gut.2005.069674","volume":"55","author":"MJ Walch","year":"2006","unstructured":"Walch MJ, Johnson JR, Richardson MM, Lipka GM, Clouston AD, Powell EE: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006, 55: 529-535. 10.1136\/gut.2005.069674.","journal-title":"Gut"},{"key":"1850_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1053\/jhep.2003.50350","volume":"38","author":"BL Bressler","year":"2003","unstructured":"Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponsive to antiviral treatment in chronic hepatitis C. Hepatology. 2003, 38: 639-644.","journal-title":"Hepatology"},{"key":"1850_CR19","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/hep.20179","volume":"39","author":"MJ Walsh","year":"2004","unstructured":"Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jansson JR, Powell EE: Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury. Hepatology. 2004, 39: 1230-1238. 10.1002\/hep.20179.","journal-title":"Hepatology"},{"key":"1850_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1042\/CS20030326","volume":"106","author":"J Araya","year":"2004","unstructured":"Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J: Increase in long-chain polyunsaturated fatty acid n-6\/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 2004, 106: 635-643. 10.1042\/CS20030326.","journal-title":"Clin Sci (Lond)"},{"key":"1850_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1743-422X-7-36","volume":"7","author":"S Hazari","year":"2010","unstructured":"Hazari S, Chandra PK, Poat B, Datta S, Garry RF, Foster TP, Kousoulas G, Wakita T, Dash S: Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virol J. 2010, 7: 36-10.1186\/1743-422X-7-36.","journal-title":"Virol J"},{"key":"1850_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cbi.2006.11.004","volume":"165","author":"MJ Gomez-Lechon","year":"2007","unstructured":"Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV: O Conner J-E: A human hepatocellular in vitro model to investigate steotosis. Chem Biol Interact. 2007, 165: 106-116. 10.1016\/j.cbi.2006.11.004.","journal-title":"Chem Biol Interact"},{"key":"1850_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/j.1440-1746.2008.05733.x","volume":"24","author":"M Ricci","year":"2009","unstructured":"Ricci M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolitti M, Banni S, Lenardo A, Carulli N, Loria P: Differential effect of oleic acid and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterology Hepatol. 2009, 24: 830-840. 10.1111\/j.1440-1746.2008.05733.x.","journal-title":"J Gastroenterology Hepatol"},{"key":"1850_CR24","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1210\/en.2005-1494","volume":"147","author":"E Karaskov","year":"2005","unstructured":"Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A: Chronic palmitate but not the oleate exposure induces endoplasmic reticulum stress which may contribute to IRS-1 pancreatic b-cell apoptosis. Endocrinology. 2005, 147: 3398-3407.","journal-title":"Endocrinology"},{"key":"1850_CR25","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1124\/dmd.106.009670","volume":"34","author":"MT Donato","year":"2006","unstructured":"Donato MT, Lahoz A, Jimenez N, Perez G, Serralta A, Mir J, Castell JV, Gomez-Lechon MJ: Potential impact of steatosis on cytochrome p450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos. 2006, 34: 1556-1562. 10.1124\/dmd.106.009670.","journal-title":"Drug Metab Dispos"},{"key":"1850_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0168-8278(03)00460-4","volume":"39","author":"AE Feldstein","year":"2003","unstructured":"Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ: Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol. 2003, 39: 978-983. 10.1016\/S0168-8278(03)00460-4.","journal-title":"J Hepatol"},{"key":"1850_CR27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.ajpath.2010.10.029","volume":"178","author":"L Bao","year":"2011","unstructured":"Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetley R, Dash S: Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in 4 T1 metastatic breast cancer model. Am J Pathol. 2011, 178: 838-852. 10.1016\/j.ajpath.2010.10.029.","journal-title":"Am J Pathol"},{"key":"1850_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1743-422X-7-118","volume":"7","author":"PK Chandra","year":"2010","unstructured":"Chandra PK, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, Burioni R, Clementi M, Garry RF, Dash S: Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol J. 2010, 7: 118-10.1186\/1743-422X-7-118.","journal-title":"Virol J"},{"key":"1850_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.antiviral.2010.11.004","volume":"89","author":"S Liu","year":"2011","unstructured":"Liu S, Nelson CA, Xiao L, Lu L, Seth PP, Davis DR, Hagedorn CH: Measuring antiviral activity of benzimidazole molecules that alters IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Res. 2011, 89: 54-63. 10.1016\/j.antiviral.2010.11.004.","journal-title":"Antiviral Res"},{"key":"1850_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1152\/ajpendo.00644.2005","volume":"291","author":"Y Wei","year":"2006","unstructured":"Wei Y, Wang D, Topczewski F, Pagliassotti MJ: Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006, 291: 275-281. 10.1152\/ajpendo.00644.2005.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1850_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1126\/science.1103160","volume":"306","author":"U Ozcan","year":"2004","unstructured":"Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun CZ, Glimcher LH, Hotamisligil GS: Endoplamsic reticulum stress links obesity, insulin action and type 2 diabetes. Science. 2004, 306: 457-461. 10.1126\/science.1103160.","journal-title":"Science"},{"key":"1850_CR32","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/0140-6736(92)91311-U","volume":"339","author":"K Kanai","year":"1992","unstructured":"Kanai K, Kako M, Okamoto H: HCV genotypes in chronic hepatitis C and response to interferon. Lancet. 1992, 339: 1543-","journal-title":"Lancet"},{"key":"1850_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/hep.1840220406","volume":"22","author":"M Martinot-Peignoux","year":"1995","unstructured":"Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Ilotova V, Benhamou JP, Erlinger S: Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to interferon therapy in chronic hepatitis C. Hepatology. 1995, 22: 1050-1056.","journal-title":"Hepatology"},{"key":"1850_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/jhep.2003.50267","volume":"38","author":"T Poynard","year":"2003","unstructured":"Poynard T, Ratziu V, McHutchinson J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J: Effect of treatment with peg interferon or interferon alpha 2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003, 38: 75-85.","journal-title":"Hepatology"},{"key":"1850_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1053\/jhep.2002.35064","volume":"36","author":"A Monto","year":"2001","unstructured":"Monto A, Alonzo J, Watson JJ, Grunfeld G, Wright TL: Steatosis in chronic hepatitis C: relative contribution of obesity, diabetes mellitus and alcohol. Hepatology. 2001, 36: 729-736.","journal-title":"Hepatology"},{"key":"1850_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/gut.2005.069757","volume":"55","author":"T Asselah","year":"2005","unstructured":"Asselah T, Rubbia-Brandt L, Marcellini P, Negro F: Steatosis in chronic hepatitis C: why does it really matter?. Gut. 2005, 55: 123-130.","journal-title":"Gut"},{"key":"1850_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/hep.510250340","volume":"25","author":"S Mihm","year":"1997","unstructured":"Mihm S, Fayyazi A, Hartmann H, Ramodori G: Analysis of histopathological manifestation of chronic HCV infection with respect to virus genotype. Hepatology. 1997, 25: 735-739. 10.1002\/hep.510250340.","journal-title":"Hepatology"},{"key":"1850_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1096\/fj.01-0396com","volume":"16","author":"G Perlemuter","year":"2002","unstructured":"Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chr\u00e9tien Y, Koike K, Pessayre D, Chapman J, Barba G, Br\u00e9chot C: Hepatitis C virus core protein and very low density lipoprotein secretion: a model of viral related steatosis. FASEB J. 2002, 16: 185-194. 10.1096\/fj.01-0396com.","journal-title":"FASEB J"},{"key":"1850_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2893.2006.00777.x","volume":"14","author":"J Westin","year":"2007","unstructured":"Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU: Hellstrand K; DITTO-HCV Study Group: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat. 2007, 14: 29-35.","journal-title":"J Viral Hepat"},{"key":"1850_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1478-3231.2005.01219.x","volume":"26","author":"Y-J Wu","year":"2006","unstructured":"Wu Y-J, Chen L-S, Qiang WG: Effect of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int. 2006, 26: 166-172. 10.1111\/j.1478-3231.2005.01219.x.","journal-title":"Liver Int"},{"key":"1850_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1478-3231.2006.01347.x","volume":"26","author":"M Soresi","year":"2006","unstructured":"Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G: Impact of liver steatosis on the antiviral response in the hepatitis C virus\u2013associated chronic hepatitis C. Liver Int. 2006, 26: 1119-1125. 10.1111\/j.1478-3231.2006.01347.x.","journal-title":"Liver Int"},{"key":"1850_CR42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jhep.2003.11.004","volume":"40","author":"HM Patton","year":"2004","unstructured":"Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004, 40: 484-490.","journal-title":"J Hepatol"},{"key":"1850_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00042737-200502000-00004","volume":"27","author":"KC Thomopoulos","year":"2005","unstructured":"Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Mimitropoulou D, Gogos CA, Labropoulou-Karatza C: Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2005, 27: 149-153.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1850_CR44","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1073\/pnas.0409834102","volume":"102","author":"SB Kapadia","year":"2005","unstructured":"Kapadia SB, Chisari FV: Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA. 2005, 102: 2561-2566. 10.1073\/pnas.0409834102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1850_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1743-422X-8-351","volume":"8","author":"S Datta","year":"2011","unstructured":"Datta S, Hazari S, Chandra PK, Samara M, Poat B, Gunduz F, Wimley WC, Hauser H, Koster M, Lamaze C, Balart L, Garry RF, Dash S: Mechanisms of HCV\u2019s resistance to IFN-alpha in cell culture involves expression of functional IFN-alpha receptor 1. Virol J. 2011, 8: 351-10.1186\/1743-422X-8-351.","journal-title":"Virol J"},{"issue":"1","key":"1850_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.chom.2008.11.008","volume":"5","author":"J Liu","year":"2009","unstructured":"Liu J, HuangFu WC, Kumar KG, Qian J, Casey JP, Hamanaka RB, Grigoriadou C, Aldabe R, Diehl JA, Fuchs SY: Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe. 2009, 5 (1): 72-83. 10.1016\/j.chom.2008.11.008.","journal-title":"Cell Host Microbe"},{"issue":"4","key":"1850_CR47","doi-asserted-by":"publisher","first-page":"e8342","DOI":"10.1371\/journal.pone.0008342","volume":"17","author":"R Minakshi","year":"2009","unstructured":"Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S: The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS One. 2009, 17 (4): e8342-","journal-title":"PLoS One"},{"key":"1850_CR48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000096310","volume":"50","author":"H Taniguchi","year":"2007","unstructured":"Taniguchi H, Iwasaki Y, Takahashi A, Shimomura H, Moriya A, Yu PC, Umeoka F, Fujioka S, Koide N, Shiratori Y: Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C. Intervirology. 2007, 50: 32-39. 10.1159\/000096310.","journal-title":"Intervirology"},{"key":"1850_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00004836-199803000-00010","volume":"26","author":"K Morita","year":"1998","unstructured":"Morita K, Tanaka K, Saito S, Kitamura T, Kondo M, Sakaguchi T, Morimoto M, Sekihara H: Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J Clin Gastroenterol. 1998, 26: 135-140. 10.1097\/00004836-199803000-00010.","journal-title":"J Clin Gastroenterol"},{"key":"1850_CR50","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1046\/j.1365-2893.2003.00477.x","volume":"11","author":"D Fujiwara","year":"2004","unstructured":"Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K, Konishi T, Nakamura H, Korenaga M, Okuda M, Okita K: Type 1 interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat. 2004, 11: 136-140. 10.1046\/j.1365-2893.2003.00477.x.","journal-title":"J Viral Hepat"},{"key":"1850_CR51","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.3748\/wjg.v11.i25.3962","volume":"11","author":"XW Meng","year":"2005","unstructured":"Meng XW, Chi BR, Chen LG, Zhang LL, Zhuang Y, Huang HY, Sun X: Expression of interferon-alpha\/beta receptor protein in liver of patients with hepatitis C virus \u2013related chronic liver disease. World J Gastroenterol. 2005, 11: 3962-3965.","journal-title":"World J Gastroenterol"},{"key":"1850_CR52","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/hep.22877","volume":"49","author":"TM Welzel","year":"2009","unstructured":"Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT: O'Brien TR; HALT-C Trial Group: Variants in Interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C Antiviral Long-term treatment against Cirrhosis trial. Hepatology. 2009, 49: 1847-1858. 10.1002\/hep.22877.","journal-title":"Hepatology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-9-143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:08:09Z","timestamp":1630526889000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-9-143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-9-143","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,3]]},"assertion":[{"value":"19 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"143"}}